Bayer Schering Pharma is to use Genedata's Biologics Data Platform (BDP) to support biologics data management and analysis at its R&D sites worldwide, which are developing novel protein-based therapeutics for diseases such as cancer, haemophilia, and multiple sclerosis.
'The BDP is an important system for our daily operations as it makes the highly interconnected biologics R&D processes more efficient,' explained Dr Heiner Apeler, director of Molecular and Antibody Biology at Bayer Schering Pharma. 'The BDP supports our scientists in a complex, multi-site environment by providing all the necessary information and tools to streamline the biologics lead generation and optimisation process. At the same time, the BDP will provide a complete historical record of our therapeutic proteins, which will be important for downstream biologics development.'
The BDP provides a shared data storage and data exchange platform to synchronise Bayer Schering Pharma's activities starting with biologics screening all the way through to production. Developed for both antibody-based and other protein therapeutics, the platform supports key informatics tasks from library generation and laboratory logistics to biologics registration and analytics. The platform directly interacts with laboratory equipment such as screening robots and integrates into Bayer Schering Pharma's existing IT infrastructure.
